Alzheimer's Awareness Month: Q&A with Dr Sabina Brennan

September is World Alzheimer’s Month. Alzheimer’s Disease (AD) is the most well-known form of dementia. Dementia is the collective name for progressive brain conditions affecting memory, thinking, behavior and emotions. Dementia affects almost 50 million people worldwide. While aging is a major risk factor for dementia, it also affects people under 65 years. 

There are over 100 forms of dementia. AD accounts for 50-60% of all cases. At the present time there is no cure. Current treatments act to temporarily improve symptoms but drug companies and researchers around the world are actively searching for treatments that may slow or stop the progression AD. Cromos Pharma is proud to support clinical research aimed at finding new treatments and maybe one day a cure for this debilitating condition. 

To mark Alzheimer’s Awareness Month (Sept 2020) we sat down with leading psychologist, neuroscientist and best-selling author DrSabina Brennan. Dr Brennan is a brain health expert who has advised Irish and UK governments on policies relating to aging and dementia.  She is the Irish national representative on the Medical and Scientific Advisory Panel for Alzheimer’s Disease International.

 How did you become interested in brain health research?

“In 2007 I got a scholarship to do a PhD in Trinity College Dublin looking at how the brain and cognitive function 

change as we age. The title of my PhD was quite the mouthful “Neurocognitive and Electrophysiological Indices of Cognitive Performance in Ageing.” I found myself drawn to the literature on cognitive reserve and dementia risk reduction. I found it difficult to understand how this important health information wasn’t in the public domain, wasn’t common knowledge especially as some of the findings were made in the 1980s.  

While scientists were doing great work, they spent much of their time talking to other scientists about their research at niche conferences and in academic journals, mostly inaccessible to the general public. Of course, this kind of academic discourse is absolutely essential for scientific progress, but the scientific literature and research on brain health and dementia can be complex and not easy for everyone to follow. 

 I felt compelled to address this by translating academic and scientific jargon into easy-to-understand, practical information to improve your brain health. As soon as I got my PhD I made a successful application to the European Commission to coordinate a multi-national, multi-lingual project to develop online brain health resources which are available free online and are used in five continents by health providers, governments and NGOS including Ireland’s own dementia awareness campaign Understand Together.”   

How would you characterise the current state of clinical research into dementia and in particular AD?

“I believe it remains underfunded. The current pandemic has scuppered a lot of research including my own. Before we went into lock down, I was leading Brain Fit, at Trinity College Dublin. This large-scale study which was co-funded by Genomics Medical Ireland and Science Foundation Ireland aimed to characterise the relationship between brain health, lifestyle, genomics and dementia. Unfortunately, due to social distancing requirements we can no longer collect data from our participants who are aged in their 60s, 70s, 80s and 90s as planned. So, our study like many others is on pause indefinitely.”

 What are your hopes for the future of clinical research into AD? 

“First of all, that it can resume in a meaningful way. Secondly, that research investment is increased in line with the impact and burden of the disease. That there is a committed focus on and investment in primary and secondary prevention rather than a sole focus on treatment and cure. According to the Lancet Commission’s report published in July 2020 forty percent of all cases of Alzheimer’s disease are attributable to 12 modifiable factors – I would like to see research focused on understanding how best to get individuals to change their behaviour in order to reduce their risk.”

Recruiting participants for clinical research is always challenging but particularly so with AD- what are your thoughts regarding patient and practitioner engagement to encourage participation in CTs. 

“COVID-19 has changed the landscape completely on this. But let’s pretend that we are back living in a ‘normal’ world. I think that there needs to be greater patient involvement in all aspects of the research  - not just as participants – but as fellow experts who are actively involved throughout the process even before funding is granted (e.g. guiding the research questions to be addressed and research to be prioritised).” 

Finally, what are your top tips for brain health?

1.     Activity

Get physically active

Physical exercise has a direct benefit on brain structure & function. It stimulates neuroplasticity and creates a nourishing environment for new brain cells. It is associated with better cognitive function and reduced stress, anxiety and depression

Stay socially engaged

Just 10 minutes social interaction can boost brain performance. Social isolation is associated with cognitive impairment and the risk to health is comparable to the risks associated with smoking and obesity.

 Go Mental

Challenging your brain, learning new things and seeking out novelty are critical for brain health. These activities promote neuroplasticity, help build brain and cognitive reserves and maintain brain volume. 

2.     Lifestyle

Love your heart

What’s good for your heart is good for your brain. You brain needs a constant supply of oxygen and nutrients, so a healthy cardiovascular system is critical to brain performance.

 Cherish sleep

When you sleep your brain has a job of work to do. New information that you have taken in has to be sorted, discarded or consolidated as memories to free up space to take in new information and learn new things the following day. Your brain also clears metabolic waste and toxins while we sleep.

Choose Balance

Your brain thrives on regularity, so feed it, water it, and rest it at regular intervals. Also fund balance between work and play, technology and nature, being social and being alone, water and alcohol etc.

 3.     Attitude

 Manage Stress

Stress is not bad in and of itself, but poorly managed chronic stress changes the brain structurally and functionally in ways that impair our ability to learn and remember.

 Be present

Focusing on what you are doing while you are doing it is a natural antidote to stress. Being in the moment also keeps negative thoughts and memories at bay and reduces anxiety, stress and depression


Boosts the growth of brain cells, makes your brain more resilient, releases feel good hormones, lowers blood pressure, boosts immune function, protects against stress, anxiety, and depression.

Find out more about brain health at

 About Dr Sabina Brennan:

Dr Sabina Brennan is a psychologist, neuroscientist, host of the Super Brain podcast and author of the No 1 best-seller 100 Days to a Younger Brain. Dr Brennan’s leads Brain Fit, a study of brain health, lifestyle, genomics and dementia. Her mission to promote brain health, through quirky animations, talks and online resources, has won her awards for science communication and recognition of the societal impact of her work.  

Dr Brennan is a passionate advocate and volunteers on multiple committees and panels. She has advised both the Irish and UK governments on matters related to ageing, brain health and dementia and is the Irish national representative on the Medical and Scientific Advisory Panel for Alzheimer’s Disease International. Her next book Beating Brain Fog (Orion Spring) will be published 4th March 2021.


Other News:

JP Morgan Healthcare Conference: Virtual Booth and Daily Presentations

We have been meeting you at the JP Morgan Healthcare Conference for the past 11 years and there is no way we are going to break with this tradition. Meet us at the CROMOS PHARMA VIRTUAL BOOTH January 11th through 14th from 8 am to 5 pm(PST). Learn about some of the most vital issues in clinical research by attending our daily presentations or stop by anytime for a chat.


Seasons Greetings from Cromos Pharma

Seasons Greetings from everyone at Cromos Pharma. Watch our holiday video here>>

Watch: The benefits of Cromos Pharma and Avance Clinical's biotech initiative

In October we launched an exciting collaboration with Avance Clinical to offer biotechs a scalable clinical trials solution. The collaboration allows biotechs to quickly start their pre-IND early phase studies in Australia, then expand to Central/Eastern Europe to access the large patient populations for their Phase 2 and 3 studies. In this new video you can learn more about the benefits of this initiative.


World AIDS Day 2020: Remarkable progress but the fight continues

Tuesday 1 December marked World AIDS Day 2020. Although throughout this year our focus has been on the coronavirus pandemic, World AIDS Day is an opportunity to reflect on another pandemic where a virus passed from animals to humans with devastating consequences. To date 77 million people worldwide have been infected with HIV. In spite of innovative new treatments 35 million people have died from the virus. 


Thanksgiving Greetings

Thanksgiving Greetings from everyone at Cromos Pharma. Watch our video here.

World Pancreatic Cancer Awareness Day 2020

Thursday 19 November 2020 is World Pancreatic Cancer Awareness Day. Here at Cromos Pharma we are proud to play our part in supporting clinical trials aimed at finding better treatments for pancreatic cancers. 


FDA Offers Guidance to Enhance Diversity in Clinical Trials

The FDA released a statement (9 November 2020) outlining its commitment to promoting greater diversity in medical product development and issuing a new guidance document outlining the agency's thinking on encouraging greater inclusivity “Enhancing the Diversity of Clinical Trial Populations--Eligibility Criteria, Enrollment Practices, and Trial Designs,”

Cromos Pharma and Avance Clinical share details of innovative collaboration at BIO-Europe 2020

Cromos Pharma and Avance Clinical announced details of their innovative collaboration to offer biotechs scalable clinical trial solutions at BIO-Europe 2020.

Orphan Drugs Market to Reach USD 340.84 Billion by 2027

The global orphan drugs market size is projected to reach USD 340.84 billion by the end of 2027. Increasing number of regulatory approvals will have a positive impact on the growth of the overall market in the coming years according to a new report from Fortune Business Insights

Cromos Pharma and Avance Clinical launch scalable clinical trial solution for biotech

Cromos Pharma is delighted to announce a new collaboration with Avance Clinical providing a scalable clinical trial solution for biotech.

Video: Cromos Pharma and Avance Clinical Collaboration

Cromos Pharma and Avance Clinical are joining forces to offer a scalable clinical trial solution for biotechs. Watch the video to find out more>>

Watch Webinar: Where in the world should I locate my pivotal clinical trial?

If you missed the live webinar “Where in the world should I locate my pivotal clinical trial?” you can now watch the recording by clicking hereThe webinar hosted by the Society of Physician Entrepreneurs (SoPE) and Workforce Genetics features Cromos Pharma's CEO Vlad Bogin, M.D, FACP. 


Watch our video: Navigating an era of uncertainty

We are pleased to share with you our new video Cromos Pharma: Helping to navigate an era of uncertainty.


Webinar: Where in the world should I locate my pivotal clinical trial?


EU cancer estimates for 2020 reveal 2.7 million new cases

The European Joint Research Council released its 2020 burden of cancer estimates on 22 July, 2020. The report revealed The cancer burden is estimated to have risen to 2.7 million new cases (all types, excluding non-melanoma skin cancer) and 1.3 million deaths in 2020. Female breast cancer remains the most commonly diagnosed.

FDA proposes new rule on reporting requirements to support Right to Try

On July 23, the U.S. Food and Drug Administration (FDA) announced a new proposed rule that would require sponsors and manufacturers who provide an ‘‘eligible investigational drug’’ under the Right to Try Act to submit an annual summary of such use to FDA.

European medicines agencies launch public consultation on joint strategy

The European Medicines Agency (EMA) and the Heads of Medicines Agencies (HMA) have developed a joint strategy for the next five years. It was released for a two-month public consultation period on 6, July, 2020.

Two new reports find impacts of COVID-19 on clinical trials easing slightly

Two new reports released by GlobalData Healthcare and Medidata find evidence of COVID-19 impacts on clinical trials easing slightly. 

Risk Based Monitoring- a data-centric approach to monitoring

In this Insights@CromosPharma article our Chief Operating Officer Stephanie Finnegan explores the role of Risk Based Monitoring (RBM) in clinical trials, how it has been utilized in response to the current coronavirus pandemic, and how the experience may shape the industry's approach to RBM in the future.

Cromos Pharma Recruits over 300 Patients in Under Two Months into a COVID-19 Clinical Trial

Cromos Pharma, an international CRO, is pleased to announce unprecedented recruitment in a phase IIb trial in patients with moderate to severe COVID-19 infection.

Connect with Cromos Pharma at BIO Digital 2020

Cromos Pharma is delighted to be participating in BIO Digital 2020, June 8-12 2020. 

Cromos Pharma celebrates International Clinical Trials Day 2020

Today (20 May, 2020) marks International Clinical Trials Day 2020. Cromos Pharma wishes to express its gratitude to everyone who participates in  and conducts clinical trials that help turn research into reality and make lifesaving and life-changing medical treatments available to patients all over the world.

First patients enrolled in Cromos Pharma managed Covid-19 trial

Cromos Pharma is proud to be part of the global search for effective COVID-19 treatments. Today (24 April, 2020) we are pleased to announce the enrollment of the first patients in clinical trials designed to be find drugs to treat the symptoms of coronavirus.

Cromos Pharma insights on master protocols

Master protocols are disrupting the clinical trial space by offering a more comprehensive and adaptive approach to studying treatments for the most complex of diseases. Cromos Pharma is delighted to share with you a recently published article on the topic by CEO Dr Vlad Bogin.

Cromos Pharma supporting World Immunization Week

Vaccines are some of our most powerful weapons against deadly diseases. Cromos Pharma salutes all those involved in the development, administration and promotion of vaccines all over the world.

Cromos Pharma wishes you a safe and healthy Easter and Passover

At the most difficult time, the entire Cromos Pharma Team wishes all our patients, clients, investigators, site personnel and partners a safe and healthy Easter and Passover.

European Medicines Agency launches new regulatory science strategy

The European Medicines Agency (EMA) recently (31 March 2020) published its Regulatory Science Strategy to 2025. The strategy provides a plan for advancing regulatory science over the next five years, covering both human and veterinary medicines.

Cromos Pharma to run COVID-19 trial

Cromos Pharma is pleased to announce that it has been enlisted to run a clinical trial of a repurposed drug candidate to treat COVID-19.  

Cromos Pharma committed to delivering in the face of COVID-19 challenges

Cromos Pharma has been closely following the COVID-19 outbreak as it continues to spread across the globe.

Cromos Pharma launches new series to explore the latest developments in clinical trials sector

2020 marks the start of a new decade when we can anticipate several trends to take hold in the global clinical research market. What can we expect in terms of the market in terms of growth and trends? Throughout 2020 Cromos Pharma’s team of experts will look at some of the major trends dominating the current market and future influences on clinical research.

Celebrating the Women of Cromos Pharma on IWD 2020

On the occasion of International Women’s Day (8 March 2020) we at Cromos Pharma are celebrating the enormous contribution of our female team members.

Cromos Pharma launches a new office in Warsaw, Poland

Cromos Pharma, an international provider of clinical trial and drug development services, today (04 MARCH 2020) announced the opening of its new office in Warsaw, Poland. The opening of the new office strengthens Cromos Pharma’s position in Poland where it has been operational since 2015.

“The establishment of the Poland office is a major development in line with Cromos Pharma’s continued expansion in European and US operations marking another milestone in the sustained growth of the Company. Poland is a significant clinical trials market that has many advantages making it highly attractive to international sponsors,” said Dr. Vlad Bogin, CEO, Cromos Pharma, “Cromos Pharma looks forward to offering sponsors an extended range of our expert services through its new office to ensure effective and cost-efficient execution of clinical trials”.

With its 40 million people Poland is one of the largest clinical trials markets in Eastern Europe that has a strong track record of over 20 years in delivering high-quality research. It boasts several advantages including a large naïve population and well-developed research infrastructure. Polish patients are positively disposed to taking part in clinical trials as it offers them an opportunity to access innovative treatments otherwise not always available to them. The country has a large network of highly skilled and motivated clinical investigators and medical professionals keen to participate in clinical research. Poland also offers relatively low costs and excellent patient recruitment.

With excellent rates of patient recruitment, high-quality data, highly skilled and committed investigators, and comparatively low costs, Poland is an attractive location for sponsors. Cromos Pharma is ready to help you access these advantages through our excellent knowledge of the regulatory processes and our existing relationships with sites and investigators.

Learn more about conducting clinical trials in Poland with Cromos Pharma here.

To explore these advantages and the services Cromos Pharma can offer you please email

About Cromos Pharma

Cromos Pharma is an international Contract Research Organization (CRO) providing tailored and effective clinical trials management to support the development of drugs that transform healthcare. It offers fully integrated services with expertise in all aspects of clinical trials of all phases in a wide range of therapeutic indications. Cromos Pharma delivers rapid recruitment and excellent patient retention as well as expert study design and management. Cromos Pharma has an extensive network of offices across 15 countries and strong regional experience in Central and Eastern Europe. Its European HQ is situated in Dublin, Ireland and its US base is in Portland, Oregon with an operational base in South Florida.